Camrelizumab Biosimilar, PD-1 Monoclonal Antibody-远泰生物

搜索

热搜关键词：
P16
IRAK4
GPC3
MMP9
IL28A
EPCAM
MK167
HAS2

请登录

提醒成功

QQ登录

微信登录

同意并阅读使用条款和隐私策略

账号密码登录

微信/QQ登录

没有账号？立即注册

搜索

抗体销售咨询健康评估咨询 mRNA-LNP咨询

0731-88388785

首页 > 产品中心 > 产品详情

产品规范
Type	In Vivo - Reseach Grade Antibody
Host	CHO cells
catalog#	B00022
Application	Flow cytometry, animal model study
Aliases	programmed cell death protein 1, PD1, CD279, cluster of differentiation 279
Size/Concentration	1mg/5mg/20mg
Isotype	Human IgG4-k kappa
Storage	Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Human PD1
Formulation	PBS, pH 7.4

Description
Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018.

Description

Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018.

Camrelizumab Biosimilar, PD-1 Monoclonal Antibody B00022

规格：

1mg
5mg
20mg

数量：

说明书：

¥2275

~~¥2275~~

加入购物车

立即购买

咨询

ProMab Biotechnologies, Inc.

联系方式

CONTACT

联系电话:

0731-88388785
公司邮箱:

sales@promab.cn
公司地址:

湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼

官方微信

产品中心

Product

技术服务

service

客户留言

message

搜索

热搜关键词：
P16
IRAK4
GPC3
MMP9
IL28A
EPCAM
MK167
HAS2

请登录